Strategically Substituted Agmatine Analogs Reduce Neuropathic Pain and Show Improved Pharmacokinetics Compared to Agmatine

• Published in: The FASEB journal Vol. 36; no. S1
• Main Authors: Clements, Benjamin M., Peterson, Cristina D., Kitto, Kelley F., Wilcox, George L., Fairbanks, Carolyn A.
• Format: Journal Article
• Language: English
• Published: United States The Federation of American Societies for Experimental Biology 01-05-2022
• ISSN: 0892-6638; 1530-6860
• DOI: 10.1096/fasebj.2022.36.S1.R2557

Chronic pain remains a serious issue, affecting millions in the United States. Opioids serve as the most powerful therapeutic option but show limited efficacy in neuropathic pain and consequential side‐effects, such as tolerance, addiction, and respiratory depression. Development of novel drugs to treat pain, though, continues to stagnate. Additionally, in conditions in which opioids are required, adjuvants to reduce opioid‐induced neuroplasticity is critical. Agmatine has been shown to reduce neuropathic pain behavior and opioid tolerance, but use remains limited due to potentially reduced CNS penetration due to its hydrophilicity. Therefore, we have developed a series of agmatine‐based compounds that exhibit greater lipophilicity while exhibiting equivalent pharmacological responses (Figure 1). The goal of this study was to assess differences in pharmacokinetics and dynamics of 4 of these strategically substituted agmatines (SSAs). Our hypothesis is that these compounds will have an increased plasma half‐life and CNS distribution compared to agmatine, with equivalent reductions in neuropathic pain and opioid tolerance.
Analysis of the pharmacokinetics in rat plasma was done using serial sampling via jugular catheter. All in vivo experiments were reviewed and approved by the University of Minnesota IACUC and the ACURO of the Department of Defense. After intravenous administration, the SSAs exhibit 2‐phase distribution and elimination and have an increased elimination half‐life over agmatine (9 minutes), with SSA3 and SSA4 showing the longest (Table 1). This increased half‐life aligns with the increased lipophilicity of these compounds. Additionally, SSA2 and SSA4 show large volumes of distribution, suggesting increased CNS distribution.
To test the impact of these compounds in vivo, we induced neuropathic pain by performing spared nerve injury (SNI). SNI drives robust tactile hypersensitivity measured using the von Frey assay in the ipsilateral hind‐paw, with the contralateral paw serving as a non‐injured control. Following intravenous administration, SSA2‐4 reduced SNI‐induced hypersensitivity at similar doses to agmatine, showing equivalent pharmacological activity. Additionally, after chronic morphine treatment alongside co‐treatment with SSA1 and SSA2, opioid reduction in the warm water (52.5°C) tail flick response was preserved, representing a prevention of opioid tolerance. In conclusion, these chemical alterations to agmatine are able to improve pharmacokinetic parameters while maintaining the pharmacological reduction in neuropathic pain and opioid tolerance, suggesting potential as novel therapeutics to replace opioids in pain treatment.